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Adamantiades-Behc ¸et’s disease (ABD) is characterized by starting with oral aphthous ulceration and developing of the systemic
involvements. The pathogenesis of ABD is closely correlated with the genetic factors and the triggering factors which acquire
delayed-type hypersensitivity reaction against oral streptococci mediated by IL-12 cytokine family. HLA-B51 is associated in more
than 60% of the patients and its restricted CD8+ T cell response is clearly correlated with the target tissues. Bes-1 gene encoded
partial S. sanguinis genome which is highly homologous with retinal protein, and 65kD heat shock protein (Hsp-65) released from
streptococci is playing an important role with human Hsp-60 in the pathogenesis of ABD. Although Hsp-65/60 has homologies
with the respective T cell epitope, it stimulates peripheral blood mononuclear cells (PBMCs) from ABD patients. On the other
hand, some peptides of Hsp-65 were found to reduce IL-8 and IL-12 production from PBMCs of ABD patients in active stage.
1.Introduction
Behc ¸et’s disease [1] (Adamantiades-Behc ¸et’s disease [2–4])
(ABD) is a chronic and multisystematic inﬂammatory disor-
der characterized by starting with oral ulceration and devel-
ops the recurrent involvement of mucocutaneous (oral and
genital ulceration, acne-like eruption, erythema nodosum-
(EN-) like eruption, etc.), ocular, vascular, digestive, and/or
nervous system organs. Although the actual etiology is still
unclear, ABD symptoms are considered to be based on the
correlation between the genetic intrinsic factors and the
triggering extrinsic factors, because more than 60% of ABD
patients are associated with HLA-B51 [2–4]. As one of the
triggering extrinsic factors, the oral unhygienic condition
may be suspected, because periodontitis, decayed teeth,
chronic tonsillitis, and so forth are frequently noted in the
oral cavity of ABD patients [5–7]. The proportion of Strepto-
coccussanguinis(S. sanguinis)andS.mitiswaspointedtosig-
niﬁcantly increase in the oral bacteria ﬂora of ABD patients
inourcountry[8–10].S.sanguiniswaspreviouslyrecognized
as species of the genus Streptococcus named “S. sanguis”
and the strain isolated from ABD patients was diﬀerent
from reference ATCC strains in DNA homology and sugar
constituents, which indicate uncommon serotype KTH-1
(so-calledBD113-20strain)[8–10].Regardingtheincreasing
of the microorganism in the oral cavity of ABD patients, it
may be diﬀerent from ethnic population, because S. mutans
is reported tobe increased in Turkey[7]. Most of the patients
including recurrent aphthosis (RA) tend to acquire delayed
type hypersensitivity (DTH) against streptococci [5, 6, 11–
13]. The serum-antibody titers against streptococci were also
elevated in ABD patients [5–7]. The 65kDa of a heat shock
protein(Hsp-65)relatedtoS.sanguiniscanbedetectedalong
with counterpart human Hsp-60 which might reactively
appear in the sera and lesions of ABD patients [14, 15]. The
lesions are histologically considered to be DTH reaction with2 Clinical and Developmental Immunology
Figure 1: Streptococcal colonies appeared from saliva of an ABD
patient in MSagar dish. According to the instructionof the MS agar
(Difco Lab.), mainly 3 kinds of bacterial colonies are diﬀerentiated
as blue crystal (probably S. mitis, etc.), gum-drop (S. salivarius,
etc.), and dip (micrococcus species, etc.) shapes at 3–5 day culture.
perivascular mononuclear cell inﬁltration, but neutrophils
are also inﬁltrated in the early stage, as seen in EN-like
eruption [12, 16, 17]. Especially, the mucous epithelial
cells of the oral ulceration, which express streptococcal
antigen and adhering molecules, are interstitially inﬁltrated
by mononuclear cells and neutrophils [12, 16]. Generally,
interleukin (IL)-12 produced by the inﬁltrated mononuclear
cells, which might be antigen presenting cells (APCs), is
thoughttoinducenaiveT(Th0)cellstoT-helpertype-1(Th-
1) cells [18] in the correlation with DTH reaction.
Hence, in this paper, we would like to focus on the role of
immune reactions againstoralstreptococci mediated by IL-12
cytokine family in the pathogenesis of ABD.
2.OralStreptococciand
SystemicSymptoms inABD Patients
In the oral cavity of ABD patients, streptococci are signif-
icantly increased [7–10] and ABD and RA patients have
hypersensitivity against them, as above described [5, 6, 11–
13]. Then, we tried to prick with their self-saliva (salivary
prick: S-prick) on the forearm skin of ABD patients using a
“prick-lansetter” with a tiny stick (OY Algol Ab Espoo/Esbo
Puh90-50991, Sweden) to avoid so-called “pathergy reac-
tion”,becausestreptococciarenaturallycontainedinthesaliva
[19]. The pathergy test has been considered as a mysterious
characteristic and diagnostic measure for ABD patients for
longtime,andthereactivephenomenamightbesuggestedas
one of autoimmune disorders. However, the reaction is seen
in 30%–40% of the patients even though the thick syringe-
needle around “20G” is used and is not always diagnostic
for ABD patients in our country [20]. The histology of
the reaction suggests DTH reaction with vascular changes
inﬁltrated by mononuclear cells as seen in EN-like eruption
of ABD patients [19].
The oral streptococci can be generally observed as main
3 kinds of streptococcal colonies appearing at 3–5 day
incubation of the saliva in MS (Mitis-Salivarius) agar with
1% tellunite solution dish which streptococci are selectively
grown (Difco Lab., Detroit, USA) (Figure 1). Forty-eight
hours after S-prick, the DTH reaction appeared at the prick
site in more than 70% of probability in ABD patients
(Figure 2(a))[ 19]. Since the skin reaction did not appear
by the sterilized saliva (SS-prick) using the syringe ﬁlter
with 0.2μm (Nalgene, Nunc International Co., USA), the S-
prick reaction is considered to be due to oral streptococci.
The histology of the biopsy specimen from the S-prick
reaction shows edema in the upper dermis and mononuclear
cell inﬁltration around and in the walls of the vessels
in the dermis (Figure 2(b)). The inﬁltrated mononuclear
cells were mainly composed of CD3+/CD4+ cells >CD68+
cells (Figure 2(c)) >CD8+ cells and no CD20+ and CD56+
cells were found, suggesting DTH reaction. This histologic
ﬁndings seem to be similar to that of the pathergy reaction
exhibiting vascular changes [21] and also similar to that of
EN-like eruption appeared on the lower leg of ABD patients
[12, 16, 17]. Generally, in EN-like eruption, mononuclear
cells were inﬁltrated around vessels in the middle dermis of
the biopsy specimen which was taken at 5th day after the
appearanceandtheinﬁltratedcellsweremainlycomposedof
CD3+/CD4+ cells >CD8+ cells > CD68+ cells. These results
provide evidence that S-prick is highly diagnostic for ABD
patients and also suggest that the pathergy reaction might
be due to cutaneous bacteria having cross immunity to oral
streptococci.
3.HLAGenotypingandStreptococcal
Hypersensitivity
HLA-B51 is supposed to be a highly associated genetic
marker of ABD patients from many diﬀerent ethnic groups
including European, Mediterranean, and Asian people [2–
4, 22, 23]. ABD has several unique epidemiologic features
distributed from Southern Europe to Japan along “the old
Silk Route” in accordance with HLA distribution [3, 4, 23]. It
is of interest that HLA-B51-transgenic mice show enhanced
neutrophil function as seen in ABD patients because HLA-
B51 gene presents at the endogenous peptides of CD8+ T
cells (regulatory T cells: T reg cells), although these mice
did not express the symptoms of ABD [24]. Regarding
the extrinsic factor, Hsp-65/60 related to the infection by
streptococci and the aﬀected tissues is detectable in the oral
mucosal ulceration and other lesions of ABD patients [14,
15].
Generally, APCs, which produce IL-12 in correlation
withDTHreaction,arethoughttobeactivatedintheperiph-
eral blood mononuclear cells (PBMCs) of ABD patients with
HLA-B51 in active disease stage, as indicated by Yasuoka et
al. [25]. On the other hand, we have obtained interesting
results that PBMCs from ABD patients in negative HLA-
B51, by stimulation with S. sanguinis antigen, exhibited
moresigniﬁcantexpressionofIL-12p40(IL-12B)mRNAand
increased protein level of IL-12p70 (70kDa composed of p35
and p40 subunits) than those of the patients with HLA-B51.
IL-12BpromotergenotypeofABDpatientswasalsoanalyzed
by polymerase chain reaction- (PCR-) based restriction
enzyme digestion. The results suggested the frequency ofClinical and Developmental Immunology 3
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Figure 2: (a) 33-year-old female ABD patient showed erythema
reaction exhibiting more than 10mm in diameter by self-saliva
(salivary prick: S-prick) 48 hours after prick. A tinny spot by
sterilized self-saliva (sterilized salivary prick: SS-prick) and control
saline (control saline prick: CS-prick) were observed. (b) Histology
of the skin reaction by S-prick from 27-year-old male ABD
patient. Edema in the upper dermis and many mononuculear cell
inﬁltration around the dilated vessels in the middle dermis were
found (HE, 100x). The magniﬁed view of the vascular change
with inﬁltrate (200x). (c) Immunochemical histology of the skin
reaction by S-prick. (avidin-biotin complex peroxydase method:
ABC method, 200x). Inﬁltration of CD3+/CD4+ cells is mainly
found around vessels and the proportion of inﬁltrate was CD3+/4+
> CD68+ > CD8+ cells. No CD20+ and CD56+ cells were found.
Table 1: Synthetic peptides of Hsp-65 derived from S. sanguinis.
MW: molecular weight (daltons) (Oguma et al., 2008) [27].
Name Location Number Amino acid sequence MW
(Da)
LO1 249–264 16 ADDVDGEALPTLVLNK 1668
UK 311–326 16 TIEALGQAARVTVDKD 1685
IIIa 365–384 20 ERLAKLSGGVAVIKVGAATE 1967
IIIb 395–413 19 EDALNATRAAVEEGIVAGG 1841
LO2 480–499 20 GEWVNMIEEGIIDPVKVSRS 2256
LO3 504–518 15 AASVASLILTTEAVV 1443
the insertion heterozygosity was signiﬁcantly higher in ABD
patients without HLA-B51, which indicates the presence of
IL-12B gene polymorphism in the promoter region. The
reaction to streptococci toward Th1-immunity mediated by
IL-12 in ABD patients seemed to be diﬀerent from HLA
background [26].
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Figure 3: IL-8 production from MONO cells activated by S.
sanguinis antigen was suppressed by LO1 and UK in a dose-
dependent manner.
The oral health is impaired in ABD patients, which
seems to be associated with the disease severity [5, 7,
9, 28] .T h eu n c o m m o ns e r o t y p e( K T H - 1 )S. sanguinis is
signiﬁcantly increased in the oral bacterial ﬂora of ABD
patientscomparedtohealthyindividuals(HIs)[8,9],andthe
serum antibodies also showed cross reactivity with the some
peptides of Hsp-65, as previously described [29]. It has been
demonstrated that the symptoms mimicking ABD appeared
in germ-free mice when S. sanguinis from ABD patients was
inoculated into their oral tissues. The immunization with S.
sanguinis through the oral membrane route is suggested to
elicit ABD-like symptoms in the animal model as seen in
ABD patients who carry S. sanguinis in the oral cavity [30].
Interestingly,thepresenceofBes-1DNAencodedS.sanguinis
gene was found in various mucocutaneous lesions including
oral and genital ulcerations and EN-like lesions and, besides,
PCR in situ hybridization revealed that Bes-1 DNA was
expressed in the cytoplasm of the inﬁltrated mononuclear
cells adhering the vascular walls in the lesions [31]. The
peptide of Hsp-60 (336–351) was found to be correlated
with the peptide of Bes-1 (229–243) and the peptide of Bes-1
(337–385) can stimulate and produce IFN-γ and IL-12 from
PBMCs of ABD patients [29].
4. Role of Hsps-65/60 inOralLesions
Hsps, which essentially scavenge denatured intracellular
proteins, are supposed to be induced by microorganisms
and mammalian tissues under a variety of stressful condition
[33], and they may be involved in the pathogenesis of some
autoimmune diseases [34]. In ABD patients, the serum levels4 Clinical and Developmental Immunology
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Figure 4: (a) and (b) Hypothesis of oral immune reaction developing the systemic manifestation in ABD. The local vascular reaction may
be caused by the antigen presenting cells immunized by S. sanguinis in the oral cavity [32].
of IgA antibodies to mycobacterial Hsp-65, which cross
reacts with selected strains of S. sanguinis, are increased
signiﬁcantly [35, 36]. APCs taken Hsps are thought to release
IL-12 and stimulate T cells and the Hsp-65/60 expressed
monocytes,whicharedetectableinvariousABDlesions,lead
T cells to undergo apoptosis after IFN-γ production [32, 35–
43]. Four peptides of Hsp-65 (111–125, 154–172, 219–233,
and 311–326) derived from S. sanguinis were recognized as
immune binding agents for T and B cell responses and the
peptides showed 50%–80% homology to the counterpart
human Hsp-60 (Table 1)[ 41–43]. These Hsps presented by
APCs can directly stimulate αβTa n dγδT cells which play
important roles in the oral mucosal immunity as the ﬁrst
defense against microorganisms. It is thought that Vγ9δ2+
T cells, a major subset of γδT cells in PBMCs, recognize the
antigens produced by bacteria and that innate and adaptive
immune responses are inﬂuenced by secreting IFN-γ from
these cells [44]. These γδT cells seemed to be elevated in
the blood ﬂow and mucocutaneous lesions of ABD patients
and these activated APCs and γδT cells might activate αβT
cells by their secretion of proinﬂammatory cytokines in the
lesions [16, 44].
5. Toll-Like Receptor (TLR) in
the InnateImmunity
Regarding the recognition system for the microorganism
antigens in humans, 10 numbers of Toll-like receptor (TLR)
family are supposed to act as innate immune receptors
by binding of particular structures present on bacteria,
viruses, fungi, and so forth [45]. Although the expression
of TLRs has been detected in various human tissues with
varying levels, the organs involved in immune response and
exposed to environment were found to have signiﬁcantly
higher TLR expression [46]. TLR-3 (ds RNA) and TLR-6
(mycoplasma, staphylococci, etc.) are also reported to be
enhanced in expression on neutrophils and monocytes of
ABD patients, when stimulated by Hsp-60 and S. sanguinis
antigen[47].APCsexpressingstreptococcalantigenbywhich
took Hsps and Bes-1 gene through the TLRs in the oral
cavity are supposed to cause the immunological reaction
as the lesions of ABD patients when they were curried
peripherally and adhered to the impaired endothelium of the
vessels.
6. Therapeutic Device
AsthepathogenesisofABDwasdescribedasabove,theDTH
reaction against oral streptococcal antigens, which might be
gained by APCs through the innate immune mechanism
in the oral cavity, takes place in the various lesions of
ABD patients. Generally, ABD patients have been treated
with the antisymptomatic drugs as followings; immuno-
supressants such as nonsteroid anti-inﬂammatory agents,
steroids, colchicine, cyclosporine A, and so forth. However,
recently antitumor necrosis factor (TNF)-α antibody hasClinical and Developmental Immunology 5
been newly added as a therapeutic tool for ABD patients
with severe uveitis [48]. On the other hand, the antibiotics
to the oral streptococci were also eﬀective, and especially,
minocycline reduced not only the growth of streptococci,
but also cytokine production from activated T cells [6].
Other studies also reported that combination therapy,
colchicines, and benzathine penicillin was eﬀective to sup-
press ABD symptoms compared to colchicine monotherapy
[49, 50].
It is of interest that the peptide of Hsp-60 (336–351)
linked to recombinant cholera toxin B (rCTB) subunit
reduced the uveitis induced by whole Hsp-60 in Lewis strain
rats, although the peptide without adjuvant is reported
to induce uveitis [42, 43]. A therapeutic trial with the
selective peptide conjugated with rCTB was done by oral
administration for ABD patients with severe uveitis. In those
patients who were controlled from the symptoms, a lack
of the peptide-speciﬁc CD4+ T cell population, decrease
in expression of Th1 type cells, and reduction of cytokines
from T cells were found [43]. Hsps might trigger both
innate and adaptive immune mechanisms in ABD, but on
the other hand, the therapeutic approaches involving Hsp
immunomodulation may be available as “oral toleration” for
ABD patients with advanced uveitis using the peptide of Hsp
(336–351) [43].
Then, we analyzed Hsp-65 derived from S. sanguinis to
ﬁnd the homologous peptides to T cell epitope of ABD
patients and also to ﬁnd how the peptides reduce the
production of cytokines from PBMCs of ABD patients in
active disease stage. The 4 peptides of Hsp-65 were shown
to signiﬁcantly stimulate and undergo CD4+ and CD8+ T
cell apoptosis in PBMCs from ABD patients. Hsp-60 also
seemed to stimulate them similarly, because the peptide of
Hsp-60 (336–351) was identiﬁed to be highly homologous
to T cell epitope [14, 35–39]. The peptides LO1 (249–264),
IIIa (365–384), IIIb (395–413), LO2 (480–499), LO3 (504–
518), and UK (311–326) corresponding to the human Hsp60
(336–351) (Table 1) were applied for activated T cells of
ABD patients in vitro to lead immunotoleration. PBMCs
from 7 active ABD patients and 5 HIs were incubated with
and without these peptides and 7 days after incubation
mainly IL-8 and IL-12 were measured and compared with
thosefromPBMCsofactiveABDpatientsincubatedwithout
the peptides as controls. Although IL-12 and IL-8 were
naturally produced from PBMCs of active ABD patients,
the signiﬁcant reduction of inﬂammatory cytokines was
found by the 5 peptides, LO1, LO2, LO3, IIIb, and UK.
To understand the suppressive mechanisms of the cytokine
production in PBMCs from active ABD patients, we tried
to ﬁnd the binding sites of the peptides on monocytes by
cDNA chips (Gene Chip; Human Genome) using NOMO-1
c e l l s( h u m a nm a c r o p h a g ec e l ll i n e )w h i c hw e r ea c t i v a t e db y
S. sanguinis antigen. The NOMO-1 cells incubated with LO1
were suppressed to produce IL-8 (Figure 3). CD58 molecule
and/or FK506-binding protein were highly expressed on the
cell surface of the NOMO-1 cells by LO1 [27, 32]. It is
considered that activated T cells of ABD patients might be
led to apopthosis by binding of LO1 on the receptors of the
cells.
7. Conclusions
Although the etiology of ABD is still obscure, the clinical
manuscripts generally start with oral aphthous ulceration
and develop systemic involvement. The close correlation
between the genetic internal and triggering external factors
is thought to be present in the pathogenesis of ABD. Most
of ABD patients tend to acquire hypersensitivity against
streptococci in the oral cavity and express DTH reaction
mediated by IL-12 in the various lesions. It might be
explained that when the APCs taken streptococcal agents
were locally curried and adhered to the damaged vessel
walls, the DTH response developed to the various clinical
symptoms (Figures 4(a) and 4(b)). The cutaneous DTH
reaction by S-prick is suggested to show the mechanism
of the regional symptoms and also the S-prick is thought
to be highly diagnostic for ABD patients rather than the
pathergy test. Hsp-65/60 seems to play an important role in
the pathogenesis of ABD. The probability of a new therapy
for ABD patients was discussed as the immune tolerance
utilizing the peptides of Hsp-65/60.
Abbreviations
ABC: Avidin-biotin complex
ABD: Adamantiades-Behc ¸et’s disease
APCs: Antigen presenting cells
DTH: Delayed type hypersensitivity
EN: Erythema nodosum
HIs: Healthy individuals
Hsp: Heat shock protein
IL: Interleukin
MS: Mitis-Salivarius
PBMCs: Peripheral blood mononuclear cells
PCR: Polymerase chain reaction
RA: Recurrent aphthosis
S-prick: Prick with self-saliva
SS-prick: Prick with sterilized self-saliva
TLR: Toll-like receptor.
Acknowledgment
TheauthorsdeeplyappreciateProfessorYoshiakiIshigatsubo
(Department of Rheumatology, Yokohama City University
School of Medicine and the director of Japanese Research
Committee of Behc ¸et’s Disease) who kindly gave us ﬁnancial
supports.
References
[1] H. Behc ¸et, “¨ Uber rezidivierende, aphthous durch ein Virus
verursachte Geschw¨ ure am Mund, am Auge und an den
Genitalien,” Dermatol Wochenschri, vol. 105, pp. 1152–1157,
1937.
[2] C. C. Zouboulis and W. Keitel, “A historical review of early
descriptions of Adamantiades-Behc ¸et’s disease,” Journal of
Investigative Dermatology, vol. 119, no. 1, pp. 201–205, 2002.
[3] C. C. Zouboulis and T. May, “Pathogenesis of Adamantiades-
Behc ¸et’s disease,” Medical Microbiology and Immunology, vol.
192, no. 3, pp. 149–155, 2003.6 Clinical and Developmental Immunology
[4] A. Kalayciyan and C. C. Zouboulis, “An update on Behc ¸et’s
disease,” Journal of the European Academy of Dermatology and
Venereology, vol. 21, no. 1, pp. 1–10, 2007.
[5] F. Kaneko, T. Kaneda, O. Ohnishi et al., “Infection allergy in
Behc ¸et’s disease,” Japanese Journal of Allergology, vol. 27, no. 4,
pp. 440–450, 1978.
[6] F.Kaneko,N.Oyama,andA.Nishibu,“Streptococcalinfection
in the pathogenesis of Behc ¸et’s disease and clinical eﬀects of
minocyclineonthediseasesymptoms,”YonseiMedicalJournal,
vol. 38, no. 6, pp. 444–454, 1997.
[7] G. Mumcu, N. Inanc, S. Z. Aydin, T. Ergun, and H.
Direskeneli, “Association of salivary S. mutans colonisation
andmannose-bindinglectindeﬁciencywithgenderinBehc ¸et’s
disease,” Clinical and Experimental Rheumatology, vol. 27,
supplement 53, pp. S32–S36, 2009.
[8] K. Yokota, S. Hayashi, Y. Araki et al., “Characterization of
Streptococcus sanguis isolated from patients with Behc ¸et’s
disease,”MicrobiologyandImmunology,vol.39,no.9,pp.729–
732, 1995.
[9] E. Isogai, S. Ohno, K. Takashi et al., “Close association
of Streptococcus sanguis uncommon serotypes with Behc ¸et’s
disease,” Biﬁdobacterium Microﬂora, vol. 9, pp. 27–41, 1990.
[10] E. Isogai, S. Ohno, and S. Kotake, “Chemiluminescence of
neutrophilsfrompatientswithBehc ¸et’sdiseaseanditscorrela-
tion with an increased proportion of uncommon selotypes of
Streptococcussanguisintheoralﬂora,”ArchivesofOralBiology,
vol. 35, pp. 43–48, 1990.
[11] E. A. Graykowski, M. F. Barile, W. B. Lee, and H. R. Stanley
Jr., “Recurrent aphthous stomatitis. Clinical, therapeutic,
histopathologic, and hypersensitivity aspects,” Journal of the
American Medical Association, vol. 196, no. 7, pp. 637–644,
1966.
[12] F. Kaneko, Y. Takahashi, Y. Muramatsu, and Y. Miura,
“Immunological studies on aphthous ulcer and erythema
nodosum-like eruptions in Behc ¸et’s disease,” British Journal of
Dermatology, vol. 113, no. 3, pp. 303–312, 1985.
[13] Y. Mizushima, K. Hoshi, T. Matsuda et al., “Skin hypersensi-
tivity to streptococcal antigens and the induction of systemic
symptoms by the antigens in Behc ¸et’s disease—a multicenter
study,” Journal of Rheumatology, vol. 16, no. 4, pp. 506–511,
1989.
[14] T. Lehner, “The role of heat shock protein, microbial and
autoimmune agents in the aetiology of Behc ¸et’s disease,”
International Reviews of Immunology, vol. 14, no. 1, pp. 21–32,
1997.
[15] S. Kaneko, N. Suzuki, N. Yamashita et al., “Characterization
of T cells speciﬁc for an epitope of human 60-kD heat shock
protein (hsp) in patients with Behc ¸et’s disease (BD) in Japan,”
Clinical and Experimental Immunology, vol. 108, no. 2, pp.
204–212, 1997.
[16] F. Kaneko, “Behc ¸et’s disease,” in A Colour Atlas of Dermato-
Immunohistology, H.UekiandH.Yaoita,Eds.,pp.84–86,Wolf
Medical Publications Ltd., London, UK, 1989.
[17] W.Lew, J.Y.Chang,J.Y.Jung,andD.Bang,“Increasedexpres-
sion of interleukin-23 p19 mRNA in erythema nodosum-like
lesions of Behc ¸et’s disease,” British Journal of Dermatology, vol.
158, no. 3, pp. 505–511, 2008.
[18] G. Trinchieri, “Interleukin-12 and its role in the generation
or TH1 cells,” Immunology Today, vol. 14, no. 7, pp. 335–338,
1993.
[19] F. Kaneko, S. Saito, A. Togashi, N. Oyama, and K. Nakamura,
“Prick test with self-saliva as an auxiliary diagnostic measure
in Behc ¸et’s disease,” Japanese Journal of Dermatology, vol. 120,
pp. 1901–1905, 2010.
[20] T. Sakane, M. Takeno, N. Suzuki, and G. Inaba, “Current
concept Behc ¸et’s disease,” New England Journal of Medicine,
vol. 341, no. 17, pp. 1284–1291, 1999.
[21] H. Serhat Inaloz, C. Evereklioglu, B. Unal, N. Kirtak, A. Eralp,
and S. S. Inaloz, “The signiﬁcance of immunohistochemistry
in the skin pathergy reaction of patients with Behc ¸et’s
syndrome,” Journal of the European Academy of Dermatology
and Venereology, vol. 18, no. 1, pp. 56–61, 2004.
[22] S. Ohno, M. Onguchi, and S. Hirose, “Close association of
HLA-Bw51 with Behc ¸et’s disease,” Archives of Ophthalmology,
vol. 100, no. 9, pp. 1455–1458, 1982.
[23] N. Mizuki, H. Inoko, and S. Ohno, “Molecular genetics (HLA)
of Behc ¸et’s disease,” in Behc ¸et’s Disease—A Guide to Its Clinical
Understanding,S .L e e ,D .B a n g ,E . - S .L e e ,a n dS .S o h n ,E d s . ,
pp. 87–100, Springer, London, UK, 2001.
[24] M. Takeno, A. Kariyone, N. Yamashita et al., “Excessive
function of peripheral blood neutrophils from patients with
Behc ¸et’s disease and from HLA-B51 transgenic mice,” Arthritis
and Rheumatism, vol. 38, no. 3, pp. 426–433, 1995.
[25] H. Yasuoka, Y. Okazaki, Y. Kawakami et al., “Autoreactive
CD8+ cytotoxic T lymphocytes to major histocompatibility
complex class I chain-related gene A in patients with Behc ¸et’s
disease,” Arthritis and Rheumatism, vol. 50, no. 11, pp. 3658–
3662, 2004.
[26] H. Yanagihori, N. Oyama, K. Nakamura, N. Mizuki, K.
Oguma, and F. Kaneko, “Role of IL-12B promoter poly-
morphism in Adamantiades-Behc ¸et’s disease susceptibility: an
involvement of Th1 immunoreactivity against Streptococcus
sanguinis antigen,” Journal of Investigative Dermatology, vol.
126, no. 7, pp. 1534–1540, 2006.
[27] K.Oguma,R.Shin,andK.Yokota,“Studiesonimmunological
responses by bacterial antigens in Behc ¸et’s disease,” Reports of
the Research Group for Behc ¸et’s disease, Japanese Ministry of
Health, Labour and Welfare, 2008, 2006-2007, pp.31–33.
[28] G. Mumcu, N. Inanc, T. Ergun et al., “Oral health is impaired
in Behc ¸et’s disease and is associated with disease activity,”
Rheumatology, vol. 43, pp. 1028–1033, 2004.
[29] E. Isogai, H. Isogai, S. Kotake et al., “Antibody cross reactivity
from sera of patients with Behc ¸et’s disease with synthetic pep-
tides that have homologies with proteins from Streptococcus
sanguis,” Journal of Applied Research, vol. 2, no. 3, pp. 1–10,
2002.
[30] E. Isogai, H. Isogai, S. Kotake, S. Ohno, K. Kimura, and K.
Oguma, “Role of Streptococcus sanguis and traumatic factors
in Behc ¸et’s disease,” Journal of Applied Research, vol. 3, no. 1,
pp. 64–75, 2003.
[31] M. Tojo, H. Yanagihori, X. Zheng et al., “Bes-1 DNA Fragment
EncodingStreptococcalAntigeninSkinLesionsFromPatients
With Behc ¸et’s Disease,” Journal of Applied Research, vol. 3, no.
3, pp. 232–238, 2003.
[32] F. Kaneko, N. Oyama, H. Yanagihori, E. Isogai, K. Yokota,
and K. Oguma, “The role of streptococcal hypersensitivity
in the pathogenesis of Behc ¸et’s disease,” European Journal of
Dermatology, vol. 18, no. 5, pp. 489–498, 2008.
[33] S. Jindal, A. K. Dudani, B. Singh, C. B. Harley, and R. S.
Gupta, “Primary structure of a human mitochondrial protein
homologous to the bacterial and plant chaperonins and to the
65-kilodalton mycobacterial antigen,” Molecular and Cellular
Biology, vol. 9, no. 5, pp. 2279–2283, 1989.
[34] J. R. Lamb and D. B. Young, “T cell recognition of stress
proteins. A link between infectious and autoimmune disease,”
Molecular Biology and Medicine, vol. 7, no. 4, pp. 311–321,
1990.Clinical and Developmental Immunology 7
[35] T. Lehner, E. Lavery, R. Smith, R. Van Der Zee, Y. Mizushima,
and T. Shinnick, “Association between the 65-kilodalton heat
shock protein, Streptococcus sanguis, and the corresponding
antibodiesinBehc ¸et’ssyndrome,”Infection and Immunity,vol.
59, no. 4, pp. 1434–1441, 1991.
[36] K. Pervin, A. Childerstone, T. Shinnick et al., “T cell epitope
expression of mycobacterial and homologous human 65-
kilodalton heat shock protein peptides in short term cell lines
from patients with Behc ¸et’s disease,” Journal of Immunology,
vol. 151, no. 4, pp. 2273–2282, 1993.
[ 3 7 ]F .P o c c i a ,P .P i s e l l i ,S .V e n d e t t ie ta l . ,“ H e a t - s h o c kp r o t e i n
expression on the membrane of T cells undergoing apoptosis,”
Immunology, vol. 88, no. 1, pp. 6–12, 1996.
[38] T. Ergun, U. Ince, E. Eks ¸ioˇ glu-Demiralp et al., “HSP 60
expression in mucocutaneous lesions of Behc ¸et’s disease,”
Journal of the American Academy of Dermatology, vol. 45, no.
6, pp. 904–909, 2001.
[39] H. Direskeneli, E. Eks ¸ioˇ glu-Demiralp, S ¸. Yavuz et al., “T cell
responses to 60/65kDa heat shock protein derived peptides in
Turkish patients with Behc ¸et’s disease,” Journal of Rheumatol-
ogy, vol. 27, no. 3, pp. 708–713, 2000.
[40] Y. Imamura, M. S. Kurokawa, H. Yoshikawa et al., “Involve-
ment of Th1 cells and heat shock protein 60 in the pathogen-
esis of intestinal Behc ¸et’s disease,” Clinical and Experimental
Immunology, vol. 139, no. 2, pp. 371–378, 2005.
[41] W. Hu, A. Hasan, A. Wilson et al., “Experimental mucosal
induction of uveitis with the 60-kDa heat shock protein-
derived peptide 336–351,” European Journal of Immunology,
vol. 28, no. 8, pp. 2444–2455, 1998.
[42] P. A. Phipps, M. R. Stanford, J.-B. Sun et al., “Prevention
of mucosally induced uveitis with a HSP60-derived peptide
linked to cholera toxin B subunit,” European Journal of
Immunology, vol. 33, no. 1, pp. 224–232, 2003.
[ 4 3 ]M .S t a n f o r d ,T .W h i t t a l l ,L .A .B e r g m e i e re ta l . ,“ O r a l
tolerization with peptide 336-351 linked to cholera toxin B
subunit in preventing relapses of uveitis in Behc ¸et’s disease,”
Clinical and Experimental Immunology, vol. 137, no. 1, pp.
201–208, 2004.
[44] I. Bank, M. Duvdevani, and A. Livneh, “Expansion of γδ T-
cells in Behc ¸et’s disease: role of disease activity and microbial
ﬂora in oral ulcers,” Journal of Laboratory and Clinical
Medicine, vol. 141, no. 1, pp. 33–40, 2003.
[45] K. A. Zarember and P. J. Godowski, “Tissue expression of
human Toll-like receptors and diﬀerential regulation of Toll-
l i k er e c e p t o rm R N A si nl e u k o c y t e si nr e s p o n s et om i c r o b e s ,
their products, and cytokines,” Journal of Immunology, vol.
168, no. 2, pp. 554–561, 2002.
[46] V. Hornung, S. Rothenfusser, S. Britsch et al., “Quantitative
expression of toll-like receptor 1–10 mRNA in cellular subsets
of human peripheral blood mononuclear cells and sensitivity
to CpG oligodeoxynucleotides,” Journal of Immunology, vol.
168, no. 9, pp. 554–561, 2002.
[47] S. Yavuz, Y. Elbir, A. Tulunay, E. Eksioglu-Demiralp, and H.
Direskeneli, “Diﬀerential expression of toll-like receptor 6 on
granulocytes and monocytes implicates the role of microor-
ganisms in Behc ¸et’s disease etiopathogenesis,” Rheumatology
International, vol. 28, no. 5, pp. 401–406, 2008.
[48] S. Ohno, S. Nakamura, S. Hori et al., “Eﬃcacy, safety, and
pharmacokinetics of multiple administration of inﬂiximab
in Behc ¸et’s disease with refractory uveoretinitis,” Journal of
Rheumatology, vol. 31, no. 7, pp. 1362–1368, 2004.
[49] M. Calguneri, I. Ertenli, S. Kiraz et al., “Eﬀect of prophy-
lacticbenzathine penicilline on mucocutaneous symptoms of
Behc ¸et’s disease,” Rheumatology International, vol. 192, pp.
125–128, 1996.
[50] G. Mumcu, N. Inanc, S. Yavuz, and H. Direskeneli, “The role
of infectious agents in the pathogenesis, clinical manifesta-
tionsandtreatmentstrategies inBehc ¸et’sdisease,” Clinicaland
Experimental Rheumatology, vol. 25, no. 4, pp. S27–S33, 2007.